Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
The Hindu Business Line  Apr 22  Comment 
Drug major Sun Pharmaceutical today said its promoter and Managing Director Dilip Shanghvi did not buy shares of the company sold by the Japanese drugmaker Daiichi Sankyo.“...Dilip Shanghvi...
GenEng News  Apr 21  Comment 
Daiichi Sankyo said today it has sold off the 8.9% stake in Sun Pharmaceutical Industries it inherited when Sun Pharma agreed to buy Ranbaxy from Daiichi Sankyo last year. Daiichi Sankyo raised $3.2 billion through the sale, according to...
The Hindu Business Line  Apr 21  Comment 
Daiichi Sankyo has emerged from a long spell of infirmity in India with its financial faculties just about intact. The Japanese group's 2008 purchase of a stake in local drugmaker Ranbaxy was once...
Yahoo  Apr 20  Comment 
Japan's Daiichi Sankyo Company Ltd is selling its stake worth up to $3.6 billion in Indian drugmaker Sun Pharmaceutical Industries Ltd (SUN.NS), a person directly involved in the deal said on Monday. The Japanese company is selling its 8.9 percent...
GenEng News  Apr 1  Comment 
Daiichi Sankyo’s U.S. subsidiary said today it will merge with its U.S.-based sister company Asubio Pharmaceuticals, whose parent is also a subsidiary of the Japanese pharma giant. Asubio’s drug development projects will be integrated into...
FiercePharma  Mar 23  Comment 
Times have been tough for Daiichi Sankyo, and they're about to get tougher for some of the Japanese company's U.S. staffers. The drugmaker is cutting its headquarters staff by 16% on Monday, with more layoffs expected in mid-April.
GenEng News  Mar 19  Comment 
Daiichi Sankyo will co-commercialize AstraZeneca’s Movantik™ (naloxegol) in the U.S., the companies said today, in an up-to-$825 million deal signed less than a month before the planned launch of the opioid-induced constipation (OIC) treatment...
Wall Street Journal  Mar 19  Comment 
AstraZeneca will partner with the U.S. unit of Daiichi Sankyo to launch constipation drug Movantik in the U.S. early next month, under a deal potentially valued at up to $825 million.
FiercePharma  Feb 9  Comment 
Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa isn't helping matters. So analysts are wondering what the company can do to plug...
FiercePharma  Jan 9  Comment 
Japanese drugmaker Daiichi Sankyo will pay the $39 million to the state and federal health programs, and a whislteblower, to settle claims it paid doctors kickbacks to prescribe some of its drugs, Reuters reports.





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki